Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 2/20 | 0.39 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664122 | 0.86 | MGLL (0.50) | SMN1; SMN2 | |
| SCHEMBL3664719 | 0.85 | MYC (0.41) | PROKR1MYCDRD2DRD1DRD4 | |
| SCHEMBL3662919 | 0.85 | HPGD (0.46) | HPGDSCD5KMT2A | |
| SCHEMBL3658680 | 0.83 | KMT2A (0.49) | MAPTSMN1; SMN2TP53KMT2A | |
| SCHEMBL3662200 | 0.81 | RAB9A (0.49) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL3659331 | 0.81 | PROKR1 (0.46) | PROKR1RIPK1MAPTKMT2A | |
| SCHEMBL3666551 | 0.80 | SMN1; SMN2 (0.42) | MAPTSMN1; SMN2TP53 | |
| SCHEMBL3665945 | 0.80 | PROKR1 (0.44) | PROKR1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3662995 | 0.78 | PARP14 (0.46) | PROKR1HPGDRIPK1 | |
| SCHEMBL3659240 | 0.77 | HPGD (0.42) | PROKR1HPGDSCD5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | claimed |
| EP-2235013-B1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | claimed |
| EP-2235013-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-10-06 | — | — | EP | claimed |
| WO-2009092565-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2009-07-30 | — | — | WO | claimed |
| EP-2083009-A1 | Substituted tetrahydroimidazopyridine compounds and their use in medicine | Grünenthal GmbH (DE) | 2009-07-29 | — | — | EP | claimed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | claimed |
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2235013-B1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2083009-A1 | Substituted tetrahydroimidazopyridine compounds and their use in medicine | Grünenthal GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | HRH4, TRPV1, QDPR | PROKR1 1965/4885MYC 4702/4885HPGD 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.